Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Candidemia

Candidemia

Part of Systemic Inflammatory Response Syndrome

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Candidemia

15 trials tracked for Candidemia: 9 in phase 3 or 4 and 4 with published results. The most-cited published study has 179 citations.

15Trials tracked
9Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 4 Phase 3 5 Phase 2 5 Other / NA 1
  1. Phase 3 Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections Completed · 179 cited
  2. Phase 4 Negative Beta Glucan in ICU Patients Completed · 64 cited
  3. Phase 3 Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis Completed · 36 cited
  4. Phase 3 Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Completed · 16 cited
  5. Phase 4 Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins Completed
  6. Phase 4 A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Completed
Show 9 more trials
  1. Phase 4 This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis Completed
  2. Phase 3 Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) Completed
  3. Phase 3 Anidulafungin In Treatment Of Candidemia In Asian Subjects Completed
  4. Phase 2 Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis Completed
  5. Phase 2 Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection Completed
  6. Phase 2 An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia Completed
  7. Phase 2 CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension Completed
  8. Phase 2 An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris Completed
  9. N/A Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Candidemia: what the trials found

Clinical management of candidemia includes several established antifungal agents including anidulafungin, micafungin, and isavuconazole. Anidulafungin has been evaluated in multiple studies showing high rates of clinical and microbiological success at various endpoints [3, 6, 9]. In one study, anidulafungin demonstrated a low incidence of relapsed response or new infections among participants 6.

Isavuconazole was evaluated in a large trial where the percentage of participants with overall response of success varied between 43.2% and 72.1% across different follow-up intervals 5. Other agents such as rezafungin for injection 7 and SCY-078 [8, 10] have been studied in clinical settings.

The agent APX001 demonstrated high treatment success rates at the end of study treatment (88.9%) in a small cohort, with consistent mycological outcomes observed through 4 weeks post-treatment 11. In a separate trial of APX001, treatment success was reported at 55% to 60% at various follow-up points, though mycological success rates were lower and decreased over time 12.

Recent results — preliminary, needs further review

  • CD101 is currently under investigation but results are not yet corroborated.
  • Voriconazole (Vfend) is undergoing evaluation in a Phase 2 trial; results are not yet corroborated.
  • A large study on an unspecified intervention reported treatment-related adverse events ranging from 0% to 92.43%; results are not yet corroborated.

For the clinician treating this condition

  • Anidulafungin is associated with high rates of clinical and microbiological success in patients with candidemia [3, 9] and low rates of relapse or new infection 6.
  • Isavuconazole shows varying levels of overall response success depending on the specific follow-up interval 5.
  • APX001 has shown high treatment success rates in small cohorts, though mycological outcomes may vary significantly between study groups [11, 12].

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Secondary analysis of 342 sepsis patients reveals limited diagnostic utility for serum biomarkers in invasive candidiasis diagnosis
Emergency Medicine RCT
Secondary analysis of 342 sepsis patients reveals limited diagnostic utility for serum biomarkers in invasive candidiasis diagnosis Doctors tested blood markers to find infection signs in sick patients quickly
Analysis of 342 sepsis patients across German ICUs shows serum antigens rise in infection, but antibodies do not. Single biomarkers offer mo…
A study of 342 sick patients found that one specific blood test works best for spotting dangerous infections. Combining multiple tests did n…
May 13, 2026
Pooled analysis review of rezafungin versus caspofungin for candidemia and invasive candidiasis
Drug Pipeline
Pooled analysis review of rezafungin versus caspofungin for candidemia and invasive candidiasis Weekly Drug Clears Blood Fungus Faster Than Daily Treatment
This review synthesizes a pooled analysis of two randomized trials evaluating rezafungin versus caspofungin in adults with candidemia or inv…
A new weekly medication clears blood infections just as well as daily shots, offering hope for shorter care.
Apr 19, 2026